Table 1

The clinical characteristics of patients

Age median (range)65 (25–87)
 Male65 (50%)
 Female64 (50%)
Tumor type
 Thoracic41 (32%)
 Genitourinary30 (23%)
 Skin24 (19%)
 Breast11 (9%)
 Gastrointestinal10 (8%)
 Head and neck6 (5%)
 Endocrine5 (3%)
 Others2 (1%)
Treatment modality
 Monotherapy66 (51%)
 Combination of ICI and non-ICI39 (30%)
  ICI and chemotherapy22
   Pembrolizumab, carboplatin, and pemetrexed15
   Pembrolizumab and eribulin6
   Pembrolizumab, fluorouracil, leucovorin, and oxaliplatin1
  ICI and targeted therapy7
   Pembrolizumab and glembatumumab vedotin2
   Pembrolizumab, abemaciclib, and anastrozole1
   Pembrolizumab and axitinib1
   Pembrolizumab and anti-cancer stem cells*1
   Atezolizumab and cabozantinib1
   Atezolizumab and bromodomain inhibitor1
  ICI and immunotherapy5
   Nivolumab and conjugated IL-2*2
   Nivolumab and anti-CSF1R*1
   Nivolumab and cancer vaccine*1
  ICI and anti-angiogenesis3
   Pembrolizumab and anti-angiopoietins*1
   Atezolizumab and bevacizumab1
   Nivolumab and bevacizumab1
  ICI and others2
   Pembrolizumab and radium-2232
 Combination of ICIs24 (19%)
  Ipilimumab and nivolumab21
  Ipilimumab and pembrolizumab1
  Ipilimumab and PD-L1 inhibitor1
  Durvalumab and tremelimumab1
Prior ICI treatment
 No112 (87%)
 Yes17 (13%)
 Ipilimumab and nivolumab9
 Radiotherapy exposure
 Concurrent radiotherapy7 (5%)
 Recent radiotherapy exposure (within a year)22 (17%)
 No recent radiotherapy exposure100 (78%)
Treatment discontinuation, causes118 (90%)
 Toxicity95 (81%)
 Progression of disease16 (14%)
 Death4 (3%)
 Unknown3 (2%)
  • *Investigational drug.

  • CSF1R, colony-stimulating factor 1 receptor; ICI, immune checkpoint inhibitor; IL-2, interleukin-2 .